Imugene (ASX:IMU) announced exceptional clinical data from the CAR T-naïve cohort of its ongoing Phase 1b basket study of azer-cel.
The clinical-stage immuno-oncology company revealed that its off-the-shelf, allogeneic CAR T-cell therapy is showing efficacy in treating advanced B-cell malignancies, particularly in patients who have exhausted multiple prior lines of treatment.
The headline results include a remarkable 100% overall response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
In the subset, all four patients achieved a partial response.
The company noted that while complete responses are historically rare in CLL/SLL, the achievement of partial responses is considered a high benchmark and has previously supported regulatory approvals under US FDA guidance.